News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,822 Results
Type
Article (13869)
Company Profile (293)
Press Release (245660)
Section
Business (79490)
Career Advice (147)
Deals (13203)
Drug Delivery (31)
Drug Development (50436)
Employer Resources (31)
FDA (5673)
Job Trends (5115)
News (144386)
Policy (10028)
Tag
Academia (901)
Alliances (21505)
Alzheimer's disease (731)
Approvals (5637)
Artificial intelligence (61)
Bankruptcy (97)
Best Places to Work (4473)
Biotechnology (241)
Breast cancer (57)
Cancer (603)
Cardiovascular disease (52)
Career advice (128)
CAR-T (48)
Cell therapy (156)
Clinical research (39715)
Collaboration (205)
Compensation (85)
COVID-19 (1015)
C-suite (58)
Cystic fibrosis (61)
Data (641)
Diabetes (65)
Diagnostics (1191)
Earnings (28754)
Events (46700)
Executive appointments (157)
FDA (5922)
Funding (210)
Gene editing (51)
Gene therapy (130)
GLP-1 (292)
Government (1064)
Healthcare (6531)
Infectious disease (1045)
Inflammatory bowel disease (89)
IPO (7187)
Job creations (859)
Job search strategy (124)
Layoffs (183)
Legal (1373)
Lung cancer (102)
Manufacturing (68)
Medical device (2548)
Medtech (2549)
Mergers & acquisitions (6099)
Metabolic disorders (204)
Neuroscience (913)
NextGen Class of 2024 (1997)
Non-profit (842)
Northern California (814)
Obesity (117)
Opinion (90)
Parkinson's disease (55)
Patents (47)
People (24939)
Pharmaceutical (48)
Phase I (13977)
Phase II (18472)
Phase III (11704)
Pipeline (169)
Postmarket research (846)
Preclinical (5924)
Radiopharmaceuticals (204)
Rare diseases (144)
Real estate (1416)
Regulatory (8179)
Research institute (932)
Southern California (749)
Startups (1965)
United States (6800)
Vaccines (165)
Weight loss (74)
Date
Today (125)
Last 7 days (536)
Last 30 days (1931)
Last 365 days (20678)
2024 (17972)
2023 (22484)
2022 (26913)
2021 (27850)
2020 (23380)
2019 (16233)
2018 (11748)
2017 (13760)
2016 (11858)
2015 (14392)
2014 (10410)
2013 (7499)
2012 (7545)
2011 (7643)
2010 (7439)
Location
Africa (148)
Asia (16785)
Australia (2822)
California (1843)
Canada (655)
China (137)
Colorado (70)
Connecticut (72)
Europe (36171)
Florida (198)
Georgia (53)
Illinois (113)
Indiana (53)
Kansas (54)
Maryland (278)
Massachusetts (1539)
Michigan (45)
Minnesota (83)
New Jersey (497)
New York (552)
North Carolina (384)
Northern California (814)
Ohio (73)
Pennsylvania (386)
South America (207)
Southern California (749)
Texas (192)
Washington State (199)
259,822 Results for "vlp therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
Bavarian Nordic A/S announced the initial safety and immunogenicity results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of a virus-like particle -based chikungunya virus vaccine candidate CHIKV VLP in healthy adults ≥65 years of age.
June 20, 2023
·
4 min read
Genetown
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
HilleVax, Inc. and Chengdu Kanghua Biological Products Co., Ltd. announced the entry into an exclusive license agreement for rights to Kangh’s hexavalent virus-like particle vaccine candidate for norovirus, referred to by HilleVax as HIL-216, outside of Greater China.
January 8, 2024
·
7 min read
Drug Development
PathoVax’s Licensed HPV Vaccine Receives FDA Clearance of HPV16 RG1-VLP Investigational New Drug Application
PathoVax LLC (“PathoVax”) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for its licensed monovalent component- HPV16 RG1-VLP and concluded that a Phase 1 clinical trial in the United States and Austria is now given the go-ahead to proceed.
March 29, 2023
·
4 min read
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the rolling submission process which was initiated in April 2024 with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older.
June 17, 2024
·
4 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Drug Development
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Icosavax, Inc. announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus and human metapneumovirus in older adults.
December 12, 2023
·
6 min read
FDA
Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut.
January 26, 2022
·
5 min read
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older.
April 29, 2024
·
3 min read
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency
Bavarian Nordic A/S announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted accelerated assessment for the upcoming Marketing Authorisation Application for CHIKV VLP, the Company’s investigational chikungunya vaccine.
February 23, 2024
·
3 min read
Drug Development
Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV).
December 13, 2022
·
6 min read
1 of 25,983
Next